Patents by Inventor Norbert Poellinger
Norbert Poellinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139217Abstract: Pharmaceutical formulation in the form of a solid dispersion, wherein the solid dispersion comprises in admixture a cannabinoid, an amphiphilic block copolymer as a solubilizer and a water-soluble film former. A method for preparing a formulation as defined, wherein the method comprises the following steps: (i) preparing a liquid composition comprising the cannabinoid, the amphiphilic block copolymer and a solvent capable of at least partially dissolving the cannabinoid and the amphiphilic block copolymer; (ii) introducing the liquid composition into a fluid bed granulator; (iii) removing solvent to obtain a solid dispersion in particulate form; and (iv) recovering the solid dispersion in particulate form from the fluid bed granulator.Type: ApplicationFiled: April 19, 2022Publication date: May 2, 2024Applicant: ADD Advanced Drug Deliver Technologies LTD.Inventors: Reinhard Nowak, Mirko Nowak, Jesko Jay Nowak, Norbert Pöllinger
-
Patent number: 11957792Abstract: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.Type: GrantFiled: April 19, 2013Date of Patent: April 16, 2024Assignee: Glatt AGInventors: Frédéric Gerber, Marie Guhmann, Norbert Pöllinger
-
Publication number: 20230201284Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS). Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.Type: ApplicationFiled: May 11, 2020Publication date: June 29, 2023Applicant: ADD Advanced Drug Delivery Technologies Ltd.Inventors: Reinhard Nowak, Mirko Nowak, Jesko Jay Nowak, Norbert Pöllinger
-
Publication number: 20230181485Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from COVID-19, a disease caused by the coronavirus SARS-Cov-2. Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from COVID-19.Type: ApplicationFiled: May 11, 2021Publication date: June 15, 2023Applicant: ADD Advanced Drug Delivery Technologies Ltd.Inventors: Reinhard Nowak, Mirko Nowak, Jesko Jay Nowak, Norbert Pöllinger
-
Publication number: 20230181484Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from COVID-19, a disease caused by the coronavirus SARS-Cov-2. Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from COVID-19.Type: ApplicationFiled: May 11, 2020Publication date: June 15, 2023Applicant: ADD Advanced Drug Delivery Technologies Ltd.Inventors: Reinhard Nowak, Mirko Nowak, Jesko Jay Nowak, Norbert Pöllinger
-
Publication number: 20230172873Abstract: Uses and formulations of cannabinoids, in particular of cannabidiol, are provided. The cannabinoids, in particular cannabidiol, are used for the treatment of patients suffering from inflammatory conditions associated with autoimmune diseases, chronic inflammatory diseases and inflammatory conditions in connection with infections, including cytokine release syndrome (CRS). Formulations are especially for oral administration of cannabinoids, in particular of cannabidiol. These formulations are useful for treating patients suffering from conditions as referred to above.Type: ApplicationFiled: May 11, 2021Publication date: June 8, 2023Applicant: ADD Advanced Drug Delivery Technologies Ltd.Inventors: Reinhard Nowak, Mirko Nowak, Jesko Jay Nowak, Norbert Pöllinger
-
Publication number: 20220323361Abstract: A process for the continuous production of an active ingredient granulate is provided, which comprises the following steps: (a) preparing a spray composition by dissolving or dispersing an active ingredient and optionally one or more excipients in a liquid; (b) providing solid particles in a process space; (c) introducing droplets of the spray composition into an injection zone of the process space in which the liquid evaporates; (d) repeated guiding of the solid particles past the sprayed droplets in the process space with the aid of a process gas jet, so that at least a portion of the droplets, which may have already lost part of the liquid contained, comes into contact with solid particles and larger solid particles are formed through agglomeration; (e) removing the active ingredient granulate from the process space in the form of solid particles, wherein the active ingredient comprises metformin or an acid addition salt of metformin, in particular metformin hydrochloride.Type: ApplicationFiled: April 9, 2020Publication date: October 13, 2022Applicant: ADD Advanced Drug Delivery Technologies Ltd.Inventors: Reinhard NOWAK, Norbert PÖLLINGER, Annette GRAVE, Michael JACOB
-
Publication number: 20220280432Abstract: A method for the continuous production of an active ingredient granulate is provided, which comprises the following steps: (a) preparing a spray composition by dissolving or dispersing an active ingredient and optionally one or more excipients in a liquid; (b) providing solid particles in a process space; (c) introducing droplets of the spray composition into an injection zone of the process space in which the liquid evaporates; (d) repeatedly guiding the solid particles back past the sprayed droplets in the process space with the aid of a process gas jet, so that at least a portion of the droplets, which may have already lost part of the liquid contained, comes into contact with solid particles and larger solid particles are formed through agglomeration; (e) removing the active ingredient granulate from the process space in the form of solid particles, wherein the active ingredient in the form used has a Hausner factor of 1.19 or greater.Type: ApplicationFiled: April 9, 2020Publication date: September 8, 2022Applicant: ADD Advanced Drug Delivery Technologies Ltd.Inventors: Reinhard NOWAK, Norbert PÖLLINGER, Annette GRAVE, Michael JACOB
-
Publication number: 20180369151Abstract: The invention relates to an oral pharmaceutical dosage form comprising a plurality of coated particles, wherein said coated particles comprise a core which comprises a Tapentadol component and which is coated with a controlled release coating material, wherein the controlled release coating material comprises a lubricant component and a polymer component, wherein the polymer component comprises one or more cellulose ethers and/or one or more acrylates, and wherein the pharmaceutical dosage form provides controlled release of the Tapentadol component.Type: ApplicationFiled: May 29, 2018Publication date: December 27, 2018Applicant: GRÜNENTHAL GMBHInventors: Marc SCHILLER, Ulrich REINHOLD, Ulrike BERTRAM, Wolfgang PRANGE, Anika-Anina PHILIPP, Stefanie STRAUB, Annette GRAVE, Norbert POELLINGER
-
Patent number: 9649280Abstract: The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.Type: GrantFiled: May 12, 2014Date of Patent: May 16, 2017Assignee: Diurnal LimitedInventors: Hiep Huatan, Richard Ross, Martin Whitaker, Norbert Poellinger, Annette Grave
-
Publication number: 20160081942Abstract: The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.Type: ApplicationFiled: May 12, 2014Publication date: March 24, 2016Applicant: Diurnal LimitedInventors: Hiep Huatan, Richard Ross, Martin Whitaker, Norbert Poellinger, Annette Grave
-
Publication number: 20140193497Abstract: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.Type: ApplicationFiled: April 19, 2013Publication date: July 10, 2014Applicant: Glatt AGInventors: Frédéric Gerber, Marie Guhmann, Norbert Pöllinger
-
Patent number: 8741350Abstract: This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.Type: GrantFiled: August 13, 2012Date of Patent: June 3, 2014Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Martin Folger, Stefan Lehner, Annette Grave, Norbert Poellinger, Randolph Seidler
-
Publication number: 20130084332Abstract: This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.Type: ApplicationFiled: August 13, 2012Publication date: April 4, 2013Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Martin FOLGER, Stefan LEHNER, Annette GRAVE, Norbert POELLINGER, Randolph Seidler
-
Patent number: 6503918Abstract: D-mannitol having a specific surface area of not less than about 1 m2/g is disclosed. The D-mannitol shows improved compressibility and is useful as an excipient.Type: GrantFiled: December 31, 2001Date of Patent: January 7, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Tomohiro Yoshinari, Fritz Schueckler, Norbert Poellinger, Shinji Maegata
-
Publication number: 20020107420Abstract: D-mannitol having a specific surface area of not less than about 1 m2/g is disclosed. The D-mannitol shows improved compressibility and is useful as an excipient.Type: ApplicationFiled: December 31, 2001Publication date: August 8, 2002Inventors: Tomohiro Yoshinari, Fritz Schueckler, Norbert Poellinger, Shinji Maegata
-
Patent number: 6235947Abstract: D-mannitol having a specific surface area of not less than about 1 m2/g is disclosed. The D-mannitol shows improved compressibility and is useful as an excipient.Type: GrantFiled: October 23, 1998Date of Patent: May 22, 2001Assignees: Takeda Chemical Industries, Ltd., Bayer AGInventors: Tomohiro Yoshinari, Fritz Schueckler, Norbert Poellinger, Shinji Maegata
-
Publication number: 20010001106Abstract: D-mannitol having a specific surface area of not less than about 1 m2/g is disclosed. The D-mannitol shows improved compressibility and is useful as an excipient.Type: ApplicationFiled: November 30, 2000Publication date: May 10, 2001Inventors: Tomohiro Yoshinari, Fritz Schueckler, Norbert Poellinger, Shinji Maegata